Trinovium (TRIB) is positioned as a micro-cap turnaround play with existing manufacturing capacity for AI data center cooling fluids, targeting 45-55% gross margins on direct-to-chip solutions plus 75-85% margins on software monitoring platforms. Key catalysts include removal of toxic Yorkville equity line, creditor support restructuring convertible debt, strong Q1 2026 results (43% revenue growth, margin expansion), and potential hyperscaler contracts before August 18 Nasdaq deadline, though execution risk remains high as a speculative micro-cap.